ArticleEmerging infectious diseases2015
Cost-effectiveness of Chlamydia vaccination programs for young women.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.BMC public health · 2022Pooled it
- Evaluating the potential health and economic impacts of chlamydia vaccination strategies in the United States: a mathematical modeling and cost-effectiveness simulation study.Lancet regional health. Americas · 2026Article
- Vaccination as a strategy for Chlamydia trachomatis control: a global mathematical modeling analysis.BMC global and public health · 2025Article
- Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia.Scientific reports · 2024Article
- Impact of a potential Chlamydia vaccine in the USA: mathematical modelling analyses.BMJ public health · 2024Article
- In silico design and analysis of a multiepitope vaccine against Chlamydia.Pathogens and disease · 2024Article
- Ensuring equity with pre-clinical planning for chlamydia vaccines.NPJ vaccines · 2023Review
- Cost-Effectiveness Analysis of Michigan's School-Wide Sexually Transmitted Disease Screening Program in Four Detroit High Schools.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2021Article
- Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives.Vaccine: X · 2021Article
- Revisiting assumptions about age-based mixing representations in mathematical models of sexually transmitted infections.Vaccine · 2018Article
- Adaptation and Pilot Testing of a Sexual Health Intervention for Female Survivors of Violence.American journal of sexuality education · 2018Article
- Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens.Vaccines · 2017Article
- Update on Chlamydia trachomatis Vaccinology.Clinical and vaccine immunology : CVI · 2017Review
- Future prospects for new vaccines against sexually transmitted infections.Current opinion in infectious diseases · 2017Review
- Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S.American journal of preventive medicine · 2016Article
- Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.Expert review of vaccines · 2016Review
- The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps.Vaccine · 2016Review
- Guinea pig genital tract lipidome reveals in vivo and in vitro regulation of phosphatidylcholine 16:0/18:1 and contribution toMetabolomics : Official journal of the Metabolomic Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We explored potential cost-effectiveness of a chlamydia vaccine for young women in the United States by using a compartmental heterosexual transmission model. We tracked health outcomes (acute infections and sequelae measured in quality-adjusted life-years [QALYs]) and determined incremental cost-effectiveness ratios (ICERs) over a 50-year analytic horizon. We assessed vaccination of 14-year-old girls and catch-up vaccination for 15-24-year-old women in the context of an existing chlamydia screening program and assumed 2 prevaccination prevalences of 3.2% by main analysis and 3.7% by additional analysis. Estimated ICERs of vaccinating 14-year-old girls were $35,300/QALY by main analysis and $16,200/QALY by additional analysis compared with only screening. Catch-up vaccination for 15-24-year-old women resulted in estimated ICERs of $53,200/QALY by main analysis and $26,300/QALY by additional analysis. The ICER was most sensitive to prevaccination prevalence for women, followed by cost of vaccination, duration of vaccine-conferred immunity, and vaccine efficacy. Our results suggest that a successful chlamydia vaccine could be cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.